A large step closure for a universal antibody test for COVID-19

Houston Methodist has become the first academic medical center in the country to provide critically ill COVID-19 patients with plasma donated from infected patients, with antibodies made by the immune system used to kill the virus. Were used and can transfer antibody strength. In a medical, possibly life-saving therapy. Sincerely: Houston Methodist

A team led by a Houston Methodist address requires quick, easy tests on screen Plasma Donors.

A new study released by the Houston Methodist gives researchers an important step to develop a uniform, universal COVID-19 Antibody Testing. The Multiviter Collaboration has tested alternative methods for measuring COVID-19 antibody levels that are faster and easier and with the best opportunity to help patients who are infected with cheap donors to identify potential donors extensively Can be used on. SARS-CoV-2 Viruses with convulsive plasma therapy.

The findings will also determine who are the best plasma donors. There is general consensus among study authors that, after donor identification, it will most likely be used in next practice to establish targeted levels of COVID-19 antibodies considering individuals as vaccines and candidates for passive immune therapy Will need to do.

Later additional uses are likely to have the greatest social impact, the researchers say, assessing relative immunity in people infected with the SARS-CoV-2 virus and neutralizing antioxidants against SARS-CoV Identifying asymptomatic individuals with high levels of. 2.

It was also found that donors who experienced shortness of breath (or indigestion) while infected with COVID-19 and who were hospitalized or who had a serious illness were more likely to have an increased immune response and Thus, there were high levels of neutralizing antibodies. All tests. In the absence of available testing, it can be used as a contingency plan to identify such donor characteristics to determine whether patients have developed high antibody levels and to recruit plasma donors for therapeutic purposes Efforts inform.

Study author James M. at the University of Texas at Austin and US Army Medical Research Institute of Infectious Diseases in association with Penn State. Musser, MD, PhD, and Eric Salazar, MD, PhD, a Houston medical scientist Methodist, tries to find an alternative to measuring virus neutralization (VN) titers, the gold standard of COVID-19 antibody testing, because VN antibodies in blood correlate with immunity. However, such antibody testing is not widely available, as it is technically complex, requires days to set up, run, and interpret, and needs to be performed in a biosafety level 3 laboratory it occurs. This is due to the fact that the first donor plasma virus antibody levels remain unknown before infection, therefore an easier, more readily available method is needed to identify more suitable proto-plasma donors.

Therefore, the research team looked at another type of testing, called ELISA assays, that could be implemented and executed with relative ease in a high-throughput fashion and widely available in clinical laboratories worldwide And is widely used. ELISA tests, or enzyme-linked immunosorbent assays, see if antibodies to the SARS-CoV-2 protein are present and produce a quantitative measurement of those antibodies. The UT Austin research team developed an ELISA antibody test for SARS-CoV-2 and provided viral antigens for this study.

In particular, scientists observed the association of anti-spike ectodomain (ECD) and anti-receptor binding domain (RBD) IgG hemorrhage antibody titres. Spike ECD and RBD proteins are the physiological parts of the much-discussed spike protein made by SARS-CoV-2 and are important in how the virus finds its way into the body, spreads and causes COVID-19 disease, so they The major ones are targets for antibody testing and vaccine development. Blood samples for the study were identified during the institutional monitoring program of 2,814 Houston Methodist employees.

The goal of the study was to test the hypothesis that anti-ECD and anti-RBD IgG hemorrhagic antibody titers are correlated with the VN titer, making these more accessible, easier-to-perform ELISA tests that plasma donors over titers. Let’s test a surrogate marker to identify. US Food and Drug Administration threshold recommended for convocation plasma donation.

In assessing the correlation between VN antibody levels and anti-RBD and anti-ECD ELISA protein titer data, researchers found that the ELISA test for VN titers at or above FLA-recommended levels exceeded the 80% probability or comparable antibody level Was more. COVID-19 for convocation plasma. These results confirm that all three types of testing can potentially serve as a quantitative target for therapeutic and prophylactic treatments.

They also found that homogeneous donors maintain high levels of immunity over the course of several weeks and that continuous plasma donation does not significantly decrease the level of neutralization of antibodies or viruses.

Perhaps most surprising is that they identified 27 individuals on the monitoring team with high degree of immune titers in all three trials to indicate that some asymptomatic individuals may have appropriate plasma for therapeutic use and that SARS-CoV- There may be a degree of immunity relative to 2.

Ultimately, the study successfully concluded that anti-RBD or anti-ECD IgG antibody titers could serve as a surrogate for VN titers to identify suitable plasma donors, and these alternative ELISA tests for COVID-19 immunity Can provide important information.


References: “E. Salazar, SV Kuchipudi, PA Christensen, TN Eger, X. Yi, P. Zhao, Z. Jin by Z”, Sved Long, RJ Olsen, J. Chen, b. Castillo, c. Leveque, DM Towers, J. Lavinder, J.D. Golihar, J. Cardona, GC Ipolito, RH Nisley, IM Bird, D. Greenvolt, RM Rossi, A. Gontu, s. Srinivasan, IB Poojari, IM Kattadori, PJ Hudson, N. Josley, L. Pruger, K. Hui, a. Herbert, DW Bernard, J. Day, v. Kapoor and JM Mouser, 10 September 2020 Journal of Clinical Investigation.
DOI: 10.1172 / JCI141206

The findings are described in a paper titled “Correspondent plasma anti-SARS-COV-2 spike protein correlates with ectodomain and receptor binding domain IgG-related virus viruses”, appearing online 10 September. Journal of Clinical Investigation. Mushar, MD, PhD, chairman of the Department of Pathology and Genomic Medicine at Houston Methodist, is the corresponding author on the study. Eric Salazar, MD, PhD, assistant professor of pathology and genomic medicine with the Houston Methodist Research Institute, is the lead investigator who led the project, treating critically ill COVID-19 patients with convulsive plasma. Houston became the first academic medical center in the country to have plasma transfused COVID-19 patients from Methodist recovered individuals.

Other collaborators working with Mouser and Salazar on this study were Suresh V. Kuchipudi, Paul A. Christenson, Todd Ann. Eger, Shin Yi, Picheng Zhao, Xicheng Jin, S. Wesley Long, Randall J. Olson, Jian Chen, Brian Castillo, Christopher Leveke, Dalton M. Towers, Jason Lavinder, Jimmy D. Golihar, Jose Cardona, Gregory C. Ippolito, Ruth H. Nisley, Ian M. Bird, Denver Greenvolt, Randall M. Rosi, Abinay Gontu, Srinidhi Srinivasan, Indira b. Poojari, Isabella M. Kattadori, Peter J. Hudson, Nicole Joslen, Laura Pruger, Kathleen Hui, Andrew Herbert, David W. Bernard, John Dye and Vivek Dapur.

The study was supported by funding from the National Institutes of Health (grants to AI146771-01 and AI139369-01), Fondren Foundation, National Institute of Allergy and Infectious Diseases (contract number 75N93019C5050), Office of Army Research (Cooperative Agreement W911NF-) Was. 12-1-0390), seed funding from the Houston Methodist Hospital, Houston Methodist Infectious Disease Research Fund, the Houston Methodist Research Institute, and the Hooke Institute of the Life Sciences for studies on Penn State, along with Hook’s Distinguished Chair at the Global Health Award. . Funding was also provided through the CARES Act with programmatic oversight from the Military Infectious Disease Research Program.